Study Seeks New AML Therapies.
The Leukemia and Lymphoma Society announced the launch of the Beat AML Master Trial, in which several medical centers and biopharmaceutical companies will collaboratively test multiple experimental drugs in patients with the disease who are over age 60 and whose cancer has one of nine genomic signatures.
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D006801:Humans; D000070516:Intersectoral Collaboration; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D012107:Research Design; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor